000144028 001__ 144028
000144028 005__ 20240229112615.0
000144028 0247_ $$2doi$$a10.1186/s12885-019-5742-x
000144028 0247_ $$2pmid$$apmid:31185958
000144028 0247_ $$2pmc$$apmc:PMC6560914
000144028 0247_ $$2altmetric$$aaltmetric:62017541
000144028 037__ $$aDKFZ-2019-01579
000144028 041__ $$aeng
000144028 082__ $$a610
000144028 1001_ $$aPark, Ae Kyung$$b0
000144028 245__ $$aSubgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
000144028 260__ $$aHeidelberg$$bSpringer$$c2019
000144028 3367_ $$2DRIVER$$aarticle
000144028 3367_ $$2DataCite$$aOutput Types/Journal article
000144028 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1561362596_4156
000144028 3367_ $$2BibTeX$$aARTICLE
000144028 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144028 3367_ $$00$$2EndNote$$aJournal Article
000144028 520__ $$aUsing a pathway-focused approach, we aimed to provide a subgroup-specific basis for finding novel therapeutic strategies and further refinement of the risk stratification in pediatric medulloblastoma.Based on genome-wide Cox regression and Gene Set Enrichment Analysis, we investigated prognosis-related signaling pathways and core genes in pediatric medulloblastoma subgroups using 530 patient data from Medulloblastoma Advanced Genomic International Consortium (MAGIC) project. We further examined the relationship between expression of the prognostic core genes and frequent chromosome aberrations using broad range copy number change data.In SHH subgroup, relatively high expression of the core genes involved in p53, PLK1, FOXM1, and Aurora B signaling pathways are associated with poor prognosis, and their average expression synergistically increases with co-occurrence of losses of 17p, 14q, or 10q, or gain of 17q. In Group 3, in addition to high MYC expression, relatively elevated expression of PDGFRA, IGF1R, and FGF2 and their downstream genes in PI3K/AKT and MAPK/ERK pathways are related to poor survival outcome, and their average expression is increased with the presence of isochromosome 17q [i(17q)] and synergistically down-regulated with simultaneous losses of 16p, 8q, or 4q. In Group 4, up-regulation of the genes encoding various immune receptors and those involved in NOTCH, NF-κB, PI3K/AKT, or RHOA signaling pathways are associated with worse prognosis. Additionally, the expressions of Notch genes correlate with those of the prognostic immune receptors. Besides the Group 4 patients with previously known prognostic aberration, loss of chromosome 11, those with loss of 8q but without i(17q) show excellent survival outcomes and low average expression of the prognostic core genes whereas those harboring 10q loss, 1q gain, or 12q gain accompanied by i(17q) show bad outcomes. Finally, several metabolic pathways known to be reprogrammed in cancer cells are detected as prognostic pathways including glutamate metabolism in SHH subgroup, pentose phosphate pathway and TCA cycle in Group 3, and folate-mediated one carbon-metabolism in Group 4.The results underscore several subgroup-specific pathways for potential therapeutic interventions: SHH-GLI-FOXM1 pathway in SHH subgroup, receptor tyrosine kinases and their downstream pathways in Group 3, and immune and inflammatory pathways in Group 4.
000144028 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000144028 588__ $$aDataset connected to CrossRef, PubMed,
000144028 7001_ $$aLee, Ji Yeoun$$b1
000144028 7001_ $$aCheong, Heesun$$b2
000144028 7001_ $$aRamaswamy, Vijay$$b3
000144028 7001_ $$aPark, Sung-Hye$$b4
000144028 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b5$$udkfz
000144028 7001_ $$aPhi, Ji Hoon$$b6
000144028 7001_ $$aChoi, Seung Ah$$b7
000144028 7001_ $$aCavalli, Florence$$b8
000144028 7001_ $$aTaylor, Michael D$$b9
000144028 7001_ $$aKim, Seung-Ki$$b10
000144028 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-019-5742-x$$gVol. 19, no. 1, p. 571$$n1$$p571$$tBMC cancer$$v19$$x1471-2407$$y2019
000144028 909CO $$ooai:inrepo02.dkfz.de:144028$$pVDB
000144028 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144028 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000144028 9141_ $$y2019
000144028 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2017
000144028 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144028 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144028 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144028 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144028 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000144028 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000144028 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000144028 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000144028 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144028 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144028 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144028 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144028 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144028 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144028 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144028 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000144028 980__ $$ajournal
000144028 980__ $$aVDB
000144028 980__ $$aI:(DE-He78)B062-20160331
000144028 980__ $$aUNRESTRICTED